Spyre Therapeutics (SYRE) Debt to Equity (2023 - 2025)
Spyre Therapeutics (SYRE) has disclosed Debt to Equity for 3 consecutive years, with $0.03 as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Debt to Equity fell 34.13% year-over-year to $0.03, compared with a TTM value of $0.03 through Dec 2025, down 34.13%, and an annual FY2025 reading of $0.03, down 34.13% over the prior year.
- Debt to Equity was $0.03 for Q4 2025 at Spyre Therapeutics, up from $0.02 in the prior quarter.
- Across five years, Debt to Equity topped out at $0.13 in Q2 2025 and bottomed at -$0.79 in Q2 2023.
- Average Debt to Equity over 3 years is -$0.04, with a median of $0.02 recorded in 2025.
- Peak annual rise in Debt to Equity hit 1763.77% in 2025, while the deepest fall reached 67.96% in 2025.
- Year by year, Debt to Equity stood at $0.01 in 2023, then soared by 541.21% to $0.05 in 2024, then tumbled by 34.13% to $0.03 in 2025.
- Business Quant data shows Debt to Equity for SYRE at $0.03 in Q4 2025, $0.02 in Q3 2025, and $0.13 in Q2 2025.